Comparison of direct oral anticoagulants and warfarin regarding midterm adverse events in patients with atrial fibrillation undergoing catheter ablation

Yuichiro Sagawa MD1 | Yasutoshi Nagata MD1 | Tetsuo Yamaguchi MD1
Takamasa Iwai MD1 | Junji Yamaguchi MD1 | Sadahiro Hijikata MD1
Keita Watanabe MD1 | Ryo Masuda MD1 | Ryoichi Miyazaki MD1
Naoyuki Miwa MD1 | Masahiro Sekigawa MD1 | Nobuhiro Hara MD1
Toshihiro Nozato MD1 | Kenzo Hirao MD2

1Department of Cardiology, Japanese Red Cross Musashino Hospital, Tokyo, Japan
2Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan

Correspondence
Yuichiro Sagawa, Department of Cardiology, Japanese Red Cross Musashino Hospital, Tokyo, Japan.
Email: yuichiro.sagawa1111@gmail.com

Abstract
Background: Oral anticoagulants, including direct oral anticoagulants (DOACs), are usually required in atrial fibrillation (AF) patients who are at a high risk of thromboembolism (TE), even if they had undergone catheter ablation (CA). Although several studies have reported the safety and efficacy of DOACs around CA in AF patients, there are only limited data regarding the midterm incidence of TE and bleeding complications post-CA among AF patients treated with warfarin or DOACs.

Methods: We studied 629 AF patients (mean age: 65.3 ± 10.3 years; 442 men) undergoing CA, to calculate the midterm incidence of TE and bleeding complications associated with warfarin or DOACs.

Results: In total, 292 patients used warfarin and 337 used DOACs (dabigatran: 90 patients; rivaroxaban: 137; and apixaban: 110). At baseline, the CHA2DS2-VASc and HAS-BLED scores were similar between the 2 groups. During a median follow-up period of 7 months, no TE complications occurred. The warfarin group had a significantly higher bleeding event rate than did the DOACs group (all bleeding complications: 32 [11.0%] vs 15 [4.5%], respectively, \( P = .002 \)). The rate of all bleeding complications was significantly higher in the warfarin group than in the DOACs group (10.1% vs 3.7%, respectively, at 10 months; \( P = .024 \)). In Cox proportional hazards modeling, DOAC use was significantly associated with a decreased risk of bleeding (adjusted hazard ratio: 0.497; 95% confidence interval: 0.261-0.906, \( P = .022 \)).

Conclusions: Direct oral anticoagulant use in AF patients undergoing CA may be associated with a similar risk of TE as warfarin but is associated with a lower risk of bleeding.

KEYWORDS
atrial fibrillation, catheter ablation, complication, direct oral anticoagulants, warfarin

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2018 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.
Catheter ablation (CA) is an established treatment for patients with drug-refractory atrial fibrillation (AF).\(^1\)\(^-\)\(^3\) Several studies have reported that CA for AF reduced the risk of thromboembolism (TE), including stroke. Anticoagulation therapy discontinuation could be considered in some AF patients who undergo CA.\(^4\)\(^-\)\(^5\) However, AF patients with a high risk of TE or a history of stroke should continue using anticoagulant drugs, even if they have undergone CA for AF.\(^4\)\(^-\)\(^5\)

Recently, the use of direct oral anticoagulants (DOACs) is increasing as a substitute for warfarin in patients with AF,\(^6\) and several large clinical studies have evaluated the safety and efficacy of DOACs around CA for AF.\(^7\)\(^-\)\(^1\(^1\)\) However, the data are limited regarding adverse events with the long-term use of DOACs in patients requiring continuous anticoagulant drugs after CA for AF.

The purpose of this study was to compare the midterm incidence of TE and bleeding complications after CA among AF patients receiving postprocedural treatment with warfarin or DOACs.

2 | METHODS

2.1 | Subjects

We identified consecutive patients who underwent radiofrequency CA between January 2013 and July 2015 at the Japanese Red Cross Musashino Hospital. All patients were required to have at least one filled prescription for an oral anticoagulant (OAC). Patients who continued taking an OAC for at least 4 weeks prior to CA and at least 4 weeks afterward were included in this study, because we aimed to examine the relationship between adverse events and the OAC status in patients with AF after CA. Neither the type of AF (paroxysmal, persistent, or permanent) nor the number of AF ablation sessions (1st, 2nd, 3rd, or 4th) was considered when we selected patients. We obtained clinical data including the drug dosage and results of laboratory examinations from the patients' medical records. A total of 731 AF patients were identified as consecutive patients who underwent CA in this study. We excluded 102 AF patients with the following conditions from this study: those with 2 or more OACs, those with an overdose of DOACs, those in whom CA was performed without the use of an OAC, those in whom CA was performed less than 4 weeks after DOAC was started, those in whom an OAC was changed immediately after CA, and those in whom follow-up data for more than 4 weeks after CA was unavailable. Therefore, 629 AF patients were included in the current analysis. This study was approved by the institutional review board of the Japanese Red Cross Musashino Hospital, and this study complied with the ethical principles of the Declaration of Helsinki and the Japanese Ethical Guideline for Medical and Health Research Involving Human Subjects. All participants were notified that they were free to opt out of participation at any time.

2.2 | Baseline characteristics and OAC status

We collected baseline data, including demographics (age, sex, and body mass index), type of AF, the ratio of the first AF ablation session, duration of AF history, comorbidities, CHA2DS2-VASc score, HAS-BLED score, echocardiographic parameters, and brain natriuretic peptide level. The CHA2DS2-VASc score was calculated for each patient, with a total possible score of 0 to 9 points (1 point for congestive heart failure, 1 for hypertension, 1 for diabetes, 2 for ischemic stroke or transient ischemic attack [TIA], 1 for vascular disease, 1 for age 65 to 74 years, 2 for age ≥75 years, and 1 for female sex). The HAS-BLED score was calculated for each patient, with a total score of 0 to 9 points (1 point for hypertension, 1 for abnormal renal function, 1 for abnormal liver function, 1 for stroke history, 1 for bleeding history, 1 for a labile international normalized ratio [INR], 1 for age ≥65 years, 1 for use of an antiplatelet drug, and 1 for alcohol dependence).

In the current analysis, antiplatelet drugs used were aspirin, clopidogrel, ticlopidine, and cilostazol. The OAC status included warfarin and 3 DOACs: dabigatran, rivaroxaban, and apixaban. The prothrombin time-INR (PT-INR) of warfarin users was measured before CA. When analyzing the administration of warfarin, we determined that the optimal therapeutic range of the PT-INR was 1.6-2.6 for age ≥70 years and 2.0-3.0 for age <70 years, according to the Guidelines for Pharmacotherapy of Atrial Fibrillation.\(^1\(^2\)\(^-\)\(^1\(^4\)\) We selected the DOAC dose based on the manufacturer’s label recommendations. The appropriate standard dose and indicated reduced dose were defined as administration according to a standard- or reduced-dose regimen, respectively. For example, the standard dose of rivaroxaban was 15 mg/day for patients with a creatinine clearance level ≥50 mL/min. The definition of a reduced-dose regimen for each DOAC is as follows. Dabigatran is suggested for patients with any one of the following: age ≥70 years, creatinine clearance level of 30-50 mL/min, history of major bleeding, and the use of p-glycoprotein inhibitors. Rivaroxaban should be reduced in patients with a creatinine clearance level of 15-49 mL/min, and apixaban should be reduced in patients with any 2 of the following: body weight <60 kg, age ≥80 years, and serum creatinine level ≥1.5 mg/dL.

2.3 | Follow-up strategy

Follow-up data were obtained at routine or additional visits at our institution. The patients were followed from 4 weeks after CA until the end of the follow-up period (September 2016) or until the OAC was discontinued, the OAC was changed, or the next CA session was performed for recurrent AF. The OAC was discontinued at 3 to 6 months after CA in AF recurrence-free patients without the risk factors of TE. TE and bleeding complications were evaluated in patients in the warfarin and DOACs groups during the follow-up period.
2.4 Efficacy and safety endpoints

The efficacy endpoint was evaluated in terms of the incidence of TE complications, including TIA and symptomatic cerebral infarction. Patients with silent cerebral infarction as seen on magnetic resonance imaging were not included in this study. The safety endpoint was evaluated in terms of major and minor bleeding complications. The major bleeding complications were defined as fatal bleeding, symptomatic bleeding at a critical site, bleeding causing a decrease in the hemoglobin level of ≥2 g/dL, or bleeding requiring transfusion. Minor bleeding complications were defined as bleeding that did not require invasive treatment, and these complications included epistaxis, hematuria, bloody stool, bloody sputum, hematoma, subcutaneous hemorrhage, subconjunctival hemorrhage, intraoral hemorrhage, and pericardial effusion.

2.5 Statistical analysis

All continuous variables in the warfarin and DOACs groups are summarized as the mean ± standard deviation or median and interquartile range. Differences in the clinical characteristics between the 2 groups were analyzed using the Mann-Whitney U test, Chi-squared test, or Fisher’s exact test, as appropriate. A Kaplan-Meier analysis was used to summarize the midterm incidence of all bleeding complications in patients in the 2 groups, and the incidence of events was compared between the 2 groups using the log-rank test. A Cox proportional hazard model was used to evaluate the association between the use of DOACs and all bleeding complications. The results of the Cox proportional hazards modeling were given as a hazard ratio (HR) and 95% confidence interval (CI). We used the HAS-BLED score as an adjustment variable in a multivariate Cox proportional hazard model to evaluate the association between the use of DOACs and all bleeding complications. The adjusted HR: 0.497; 95% CI: 0.261-0.906, P = .022.

2.6 Clinical endpoints

Table 4 shows the results of the multivariate Cox proportional analysis for all bleeding complications. DOACs use was significantly associated with a decreased risk of all bleeding complications (adjusted HR: 0.497; 95% CI: 0.261-0.906, P = .022).
TABLE 1 Comparison of patient clinical characteristics between warfarin and DOACs group

|                                  | Total patients (n = 629) | Warfarin (n = 292) | DOACs (n = 337) | P value |
|----------------------------------|--------------------------|--------------------|----------------|---------|
| Age (y)                          | 65.3 ± 10.3              | 66.4 ± 9.9         | 64.3 ± 10.6    | .013    |
| Male                             | 442 (70.3%)              | 204 (69.9%)        | 238 (70.6%)    | .835    |
| BMI (kg/m²)                      | 23.7 ± 3.4               | 23.6 ± 3.4         | 23.8 ± 3.3     | .612    |
| Paroxysmal AF                    | 354 (56.3%)              | 125 (42.8%)        | 229 (68.0%)    | <.01    |
| 1st session                      | 459 (73.0%)              | 188 (64.4%)        | 271 (80.4%)    | <.01    |
| Duration of AF history (mo)      | 5 (2-21)                 | 8.5 (3-36)         | 4 (1-12.5)     | <.01    |
| Hypertension                     | 279 (44.4%)              | 118 (40.6%)        | 161 (47.8%)    | .069    |
| Diabetes                         | 66 (10.4%)               | 34 (11.6%)         | 32 (9.5%)      | .381    |
| Heart failure                    | 108 (17.2%)              | 62 (21.2%)         | 46 (13.7%)     | .012    |
| Stroke                           | 50 (7.9%)                | 28 (9.6%)          | 22 (6.5%)      | .158    |
| Vascular disease                 | 13 (2.1%)                | 6 (2.1%)           | 7 (2.1%)       | .989    |
| CHA2DS2-VASc score               | 2.0 ± 1.4                | 2.1 ± 1.5          | 1.9 ± 1.3      | .078    |
| HAS-BLED score                   | 1.3 ± 0.9                | 1.4 ± 1.0          | 1.3 ± 0.9      | .175    |
| Echocardiography                 |                          |                    |                |         |
| Ejection fraction (%)            | 65.8 ± 10.8              | 65.1 ± 11.7        | 66.4 ± 10.0    | .135    |
| Left atrium diameter (mm)        | 38.5 ± 6.8               | 39.5 ± 7.1         | 37.7 ± 6.4     | <.01    |
| CCr (mL/min)                     | 79.5 ± 29.1              | 74.2 ± 30.3        | 84.1 ± 27.3    | <.01    |
| BNP (pg/mL)                      | 61.3 (27.6-119.2)        | 78.7 (45.7-147.5)  | 45.2 (19.5-98.5) | <.01    |
| Duration of OAC use (mo)         | 7 (4-14)                 | 9 (5-16)           | 7 (4-13)       | <.01    |

Values are shown as the mean ± standard deviation or median (interquartile range) or n (%).

DOACs, direct oral anticoagulants; BMI, body mass index; AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years and sex category; HAS-BLED, hypertension, abnormal renal function/liver function, stroke, prior bleeding, elderly (age ≥65 years), use of antiplatelet drugs/alcohol dependence, Labile international normalized ratio; CCr, creatinine clearance; OAC, oral anticoagulant.

In addition, when we analyzed the clinical outcomes of 591 AF patients, excluding those with off-label under dose or non-suggested-dose DOACs, we obtained same results.

4 DISCUSSION

The main findings of the present study were as follows: (i) there was no significant difference in the CHA2DS2-VASc score and HAS-BLED score (including the rate of combined antiplatelet drugs) between the warfarin and DOACs groups; (ii) there was no significant difference in the prevalence of TE and major bleeding complications between the warfarin and DOACs groups during the follow-up period; (iii) patients in the warfarin group had more minor bleeding complications than did those in the DOACs group, and the rate of all types of bleeding complications was significantly higher in the warfarin group than that in the DOACs group, as assessed with the Kaplan-Meier analysis; and (iv) in a multivariate Cox proportional analysis for all bleeding complications, the use of DOACs was significantly associated with a decreased risk of all types of bleeding complications.

Randomized controlled trials, such as the RE-LY, ROCKETF AF, and ARISTOTLE, have reported the efficacy and safety of DOACs compared with warfarin.6,18-20 A previous meta-analysis reported that DOACs significantly reduced TE, including stroke, compared with warfarin, and were similar to warfarin regarding the occurrence of major bleeding complications.21 Conversely, DOACs were reported to be associated with an increased risk of gastrointestinal bleeding compared with warfarin.22 As real-world data, the Fushimi AF Registry study showed that there was no significant difference in the incidence of stroke, TE, and major bleeding complications between warfarin and DOACs.23 However, the occurrence of minor bleeding complications was not reported in that study.

The present study showed that there was no significant difference in the midterm incidence of TE and major bleeding complications between the warfarin and DOACs groups, similar to the result of the Fushimi AF Registry study. Furthermore, the prevalence of major bleeding complications was similar to that in previous studies targeting AF patients who did not undergo CA. Meanwhile, the prevalence of TE complications was lower in our study than that which has been reported in previous studies.6,18-20,23 We targeted patients undergoing CA for AF, which is why these patients experienced some reduction of TE complications compared with previous studies.24 We showed that patients in the warfarin group had significantly more minor bleeding complications than did those in the DOACs group. Although minor bleeding complications occur frequently in AF patients who are treated with an OAC, most previous studies concerning the prognosis and management of bleeding have focused on major bleeding.25-27 and the incidence of minor bleeding complications has rarely been evaluated. The ARISTOTLE trial
reported that nonmajor bleeding, including minor bleeding, was less frequent in patients who were treated with apixaban than in those who were treated with warfarin; moreover, minor bleeding is very important, as it is a frequent clinical complication and often results in adverse outcomes including mortality and major bleeding events.\textsuperscript{16} Although we were not able to prove whether the occurrence of minor bleeding was related to adverse outcomes because of the small number of patients who were included, considering this previous report, we consider that the present results are important.

In the present study, the HAS-BLED scores were similar between the 2 groups; however, creatinine clearance was lower in the warfarin group than in the DOACs group. Although creatinine clearance is generally an important factor of bleeding complications, the average value of creatinine clearance was more than 60 mL/min in the 2 groups. Thus, we speculated that the targeted patients in the present study were not at a high risk of bleeding complications in terms of renal function.

In the present study, there were some off-label under dose or non-suggested-dose DOAC users. The Fushimi AF Registry study mentioned that the use of off-label under dose DOAC might have influenced the clinical outcome.\textsuperscript{23} However, in our study, only 11% of all DOAC users were prescribed off-label under dose or non-suggested-dose DOACs; moreover, the same result was obtained.

### TABLE 2: Details of anticoagulation management

| Warfarin (n = 292) | DOACs (n = 337) | P value |
|-------------------|----------------|---------|
| PT-INR            |                |         |
| 2.01 ± 0.45       |                |         |
| Within the optimal therapeutic range | 180 (61.6%) |         |
| Below the therapeutic range | 102 (34.9%) |         |
| Above the therapeutic range | 10 (3.4%) |         |
| Dabigatran all user | 90 (26.7%) |         |
| 300 mg user       | 36 (10.7%)    |         |
| 220 mg user       | 48 (14.2%)    |         |
| 150 mg user       | 6 (1.8%)      |         |
| Rivaroxaban all user | 137 (40.7%) |         |
| 15 mg user        | 118 (35.0%)   |         |
| 10 mg user        | 19 (5.6%)     |         |
| Apixaban all user | 110 (32.6%)   |         |
| 10 mg user        | 93 (27.6%)    |         |
| 5 mg user         | 17 (5.0%)     |         |
| Off-label under dose user | 38 (11.3%) |         |
| Dabigatran user   | 20 (5.9%)     |         |
| Rivaroxaban user  | 8 (2.4%)      |         |
| Apixaban user     | 10 (3.0%)     |         |
| Co-use of antiplatelet drug | 25 (8.6%) | 20 (5.9%) .203 |

Values are shown as the mean ± standard deviation or n (%). DOACs, direct oral anticoagulants; PT-INR, prothrombin time-international normalized ratio.

### TABLE 3: Comparison of thromboembolic and bleeding complications between warfarin and DOACs group

|                      | Total patients (n = 629) | Warfarin (n = 292) | DOACs (n = 337) | P value |
|----------------------|--------------------------|--------------------|----------------|---------|
| All thromboembolic complications | 0 (0%) | 0 (0%) | 0 (0%) | – |
| Cerebral infarction | 0 (0%) | 0 (0%) | 0 (0%) |         |
| Transient ischemic attack | 0 (0%) | 0 (0%) | 0 (0%) |         |
| All types of bleeding complications | 47 (7.5%) | 32 (11.0%) | 15 (4.5%) .002 |
| Major bleeding | 10 (1.6%) | 6 (2.1%) | 4 (1.2%) .386 |
| Gastrointestinal bleeding | 4 (0.6%) | 2 (0.7%) | 2 (0.6%) |         |
| Hemoperitoneum | 1 (0.2%) | 1 (0.3%) | 0 (0%) |         |
| Cerebral bleeding | 5 (0.8%) | 3 (1.0%) | 2 (0.6%) |         |
| Minor bleeding | 38 (6.0%) | 26 (8.9%) | 12 (3.6%) .005 |
| Epistaxis | 4 (0.6%) | 1 (0.3%) | 3 (0.9%) |         |
| Hematuria | 7 (1.1%) | 6 (2.1%) | 1 (0.3%) |         |
| Bloody stool | 10 (1.6%) | 6 (2.1%) | 4 (1.2%) |         |
| Bloody sputum | 2 (0.3%) | 1 (0.3%) | 1 (0.3%) |         |
| Hematoma | 2 (0.3%) | 2 (0.7%) | 0 (0%) |         |
| Subcutaneous hemorrhage | 7 (1.1%) | 6 (2.1%) | 1 (0.3%) |         |
| Intraoral hemorrhage | 3 (0.5%) | 3 (1.0%) | 0 (0%) |         |
| Subconjunctival hemorrhage | 2 (0.3%) | 0 (0%) | 2 (0.6%) |         |
| Pericardial effusion | 1 (0.2%) | 1 (0.3%) | 0 (0%) |         |

DOACs, direct oral anticoagulants.

**FIGURE 1** Kaplan-Meier curves for all types of bleeding complications after the ablation procedure according to oral anticoagulant status. DOACs, direct oral anticoagulants.
TABLE 4 Multivariate Cox proportional analysis

| Variables                        | All types of bleeding complications | HR  | 95% CI       | P value |
|----------------------------------|-------------------------------------|-----|--------------|---------|
| DOACs use                        |                                     | 0.497 | 0.261-0.906 | .022    |
| HAS-BLED score, 1 point increase |                                     | 1.222 | 0.91-1.628  | .179    |

HR, hazard ratio; 95% CI, 95% confidence interval; DOACs, direct oral anticoagulants; HAS-BLED, hypertension, abnormal renal function/liver function, stroke, prior bleeding, elderly (age ≥ 65 years), use of antiplatelet drugs/alcohol dependence, Labile international normalized ratio.

when we analyzed the clinical outcomes of 591 AF patients, excluding those with off-label under dose or non-suggested-dose DOACs. In addition, in the present study, most of the unde dose DOAC users were in the dabigatran group. A reduced dose of dabigatran was proven to be noninferior to warfarin in previous studies. Therefore, the use of an off-label under dose or non-suggested-dose DOAC may have had little influence on the clinical outcomes of the present study.

4.1 Study limitations

The present study has several limitations. First, this study was a small-scale, retrospective, and observational study at a single institution. Therefore, the Cox proportional hazards modeling might have been biased, and special care should be taken when interpreting the present results. The adjusted HR of the HAS-BLED score was 1.222 (95% CI: 0.91-1.628, P = .179), which indicates that the HAS-BLED score showed a 22% increase in bleeding events as a 1-point increase; however, it was not statistically significant, likely due to several reasons. First, the sample size was small and all bleeding events occurred in only 47 patients in the present study. Thus, we may have lacked statistical power. Second, the mean HAS-BLED score of the AF patient group in the present study was 1.3, which was lower than that which has been reported in other studies. A low HAS-BLED score of the participants may result in a low incidence of bleeding events in this study. Second, data on the therapeutic time range in the warfarin group during the follow-up period was not available. Thus, the influences of the quality of warfarin control on clinical events are unknown. Third, adherence to an OAC regimen during the follow-up period is important; however, we did not investigate this factor. Finally, the rate of AF recurrence after CA was not investigated; therefore, the impact of AF recurrence on the clinical outcome, especially TE complications, is not known.

5 CONCLUSIONS

This retrospective study is one of the first studies to evaluate the midterm follow-up of patients with TE and bleeding events after CA. Furthermore, we found that the risk of TE complications in AF patients undergoing CA was similar among warfarin and DOACs users, whereas the risk of bleeding complications was lower in DOAC users than in warfarin users. DOACs might be suitable for patients requiring continuous OAC administration after CA for AF.

CONFLICT OF INTEREST

Authors declare no conflict of interests for this article.

ETHICAL APPROVAL

The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution, and it conforms to the provisions of the Declaration of Helsinki. Committee of Japanese Red Cross Musashino Hospital, Approval No. 29081.

ORCID

Yuichiro Sagawa http://orcid.org/0000-0002-2588-3757

REFERENCES

1. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–66.
2. Bhargava M, Di Blase L, Mohanty P, et al. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. Heart Rhythm. 2009;6:1403–12.
3. Ouyang F, Bänsch D, Ernst S, et al. Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation. 2004;110:2090–6.
4. Fiorenzo G, Davide S, Alberto B, et al. Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation. Europace. 2014;16:980–6.
5. Sjölander S, Holmqvist F, Smith JG, et al. Assessment of use vs discontinuation of oral anticoagulation after pulmonary vein isolation in patients with atrial fibrillation. JAMA Cardiol. 2017;2:146–52.
6. Cha MJ, Choi EK, Han KD, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation. Stroke. 2017;48:3040–8.
7. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627–36.
8. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvar atrial fibrillation. Eur Heart J. 2015;36:1805–11.
9. Kawabata M, Sasaki T, Maeda S, et al. Rivaroxaban for periprocedural anticoagulation therapy in Japanese patients undergoing catheter ablation of paroxysmal non-valvular atrial fibrillation. Int Heart J. 2016;57:712–6.
10. Kuwahara T, Abe M, Yamaki M, et al. Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study. J Cardiovasc Electrophysiol. 2016;27:549–54.
11. Murakawa Y, Nogami A, Shoda M, et al. Report of periprocedural oral anticoagulants in catheter ablation for atrial fibrillation: The
Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF). J Arrhythm. 2017;33:172–6.

12. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540–6.

13. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31:817–21.

14. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med. 2001;40:1183–8.

15. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.

16. Bait MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017;103:623–8.

17. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.

18. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

19. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

20. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

21. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.

22. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.

23. Yamashita Y, Uozumi R, Hamatani Y, et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients – Fushimi AF Registry. Circ J. 2017;81:1278–85.

24. Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. Eur Heart J. 2016;37:2478–87.

25. Graham DJ, Reichman ME, Wernette M, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662–71.

26. Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63:891–900.

27. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63:2141–7.

28. Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015;36:1264–72.

29. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318:1250–9.

30. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace. 2013;15:1407–11.

How to cite this article: Sagawa Y, Nagata Y, Yamaguchi T, et al. Comparison of direct oral anticoagulants and warfarin regarding midterm adverse events in patients with atrial fibrillation undergoing catheter ablation. J Arrhythmia. 2018;34:428–434. https://doi.org/10.1002/joa3.12079